Trial Profile
A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2019
Price :
$35
*
At a glance
- Drugs Sevelamer (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genzyme Corporation
- 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Apr 2015 New trial record